Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma

Published: 19 May 2025 by GSK press release

Abstract:

Second major approval for Blenrep combinations, with more expected in 2025

Copyright © Therapists Africa 2025